目次

1. Report Overview
1.1 Introduction to Checkpoint Inhibitors Market
1.2 Global Checkpoint Inhibitors Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Checkpoint Inhibitors Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered by This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain

2 Executive Summary

3 Checkpoint Inhibitors Industry Structure
3.1 Overview
3.1.1 Inhibitory Immune Checkpoint Targets
3.1.2 Immunometabolic Modulatory Targets
3.1.3 CAR-T Cells

4 Global Market Dynamics
4.1 Current Trends in the Global Market
4.2 Market Driving Factors
4.2.1 Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
4.2.2 New Products/Therapy Launch Are Gaining Tractions in the Global Market
4.2.3 Increasing Support from FDA in the Approval Procedures
4.3 Market Restraining Factors
4.3.1 Most Patients and Cancers Do Not Respond to Checkpoint Inhibitor Therapies
4.3.2 Immune-Related Adverse Events Occurred, Restraining Further Research
4.3.3 An Increased Risk of Thromboembolism
4.4 Opportunities in the Global Market
4.4.1 Unprecedented Advances in Cancer Immunotherapy
4.4.2 Unmet Medical Needs
4.4.3 New Combinations Therapies Creating New Opportunities
4.5 Challenges in the Global Market
4.5.1 Lack of Understanding in Regards to Checkpoint Inhibitors Mechanisms
4.5.2 Resistance to Immune Checkpoint Inhibitors
4.5.3 Whether irAE Presentation Correlates with ICI efficacy is a Challenge

5 Global Checkpoint Inhibitors Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

6 Global Market Breakdown by Category
6.1 Segment Overview
6.1.1 PD-1 inhibitor:
6.1.2 PD-L1 Inhibitors:
6.1.3 CTLA-4 Inhibitors:
6.1.4 Cytokines Targets:
6.1.5 Immuno Adjuvants
6.1.6 Immunomodulators
6.1.7 Pre-COVID-19 Market Scenario
6.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7 Global Market Breakdown by PD1 Inhibitors
7.1 Segment Overview
7.1.1 Introduction to PD-1/PD-L1 Agents
7.1.2 Pembrolizumab (Keytruda), Merck & Co.
7.1.3 Nivolumab (Opdivo), BMS
7.1.4 Atezolizumab (Tecentriq), Genentech
7.1.5 Cemiplimab (Libtayo), Regeneron/Sanofi
7.1.6 Pre-COVID-19 Market Scenario
7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7.2 Global Market Breakdown by PD-L1 Inhibitors
7.2.1 Avelumab (Bavencio), Merck KGaA/Pfizer
7.2.2 Durvalumab (Imfinzi), AstraZeneca
7.2.3 Pre-COVID-19 Market Scenario
7.2.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8 Global Market Breakdown by CTLA-4 Inhibitors
8.1 Segment Overview
8.1.1 Pre-COVID-19 Market Scenario
8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9 Global Market Breakdown by Cytokines Target
9.1 Segment Overview
9.1.1 Pre-COVID-19 Market Scenario
9.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10 Global Market Breakdown by Immuno Adjuvants
10.1 Segment Overview
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11 Global Market Breakdown by Immuno Modulators
11.1 Segment Overview
11.2 Pre-COVID-19 Market Scenario
11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12 Global Market Breakdown by Application
12.1 Segment Overview
12.1.1 Lung Cancer Treatment
12.1.2 Renal Cancer Treatment
12.1.3 Blood Cancer Treatment
12.1.4 Bladder Cancer Treatment
12.2 Pre-COVID-19 Market Scenario
12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13 Global Checkpoint Inhibitors Market by Region
13.1 Regional Market Size Estimation and Forecast
13.1.1 Pre-COVID-19 Market Scenario
13.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

14 North America Checkpoint Inhibitors Market Analysis
14.1 North America Market Outlook
14.2 North America Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 North America Market Breakdown by Category
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 North America Market Breakdown by PD-1 Inhibitors
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 North America Market Breakdown by PD-L1 Inhibitors
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 North America Market Breakdown by CTLA-4 Inhibitors
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 North America Market Breakdown by Cytokines Target
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 North America Market Breakdown by Application
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 North America Market Breakdown by Immuno Adjuvants
14.10.1 Pre-COVID-19 Market Scenario
14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 North America Market Breakdown by Immunomodulators
14.11.1 Pre-COVID-19 Market Scenario
14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 US Checkpoint Inhibitors Market Analysis
14.12.1 Clinical Use of Checkpoint Inhibitors is Growing Rapidly in the US
14.12.2 Acceptance of Checkpoint Inhibitors for Treating Cancer
14.12.3 Pre-COVID-19 Market Scenario
14.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 Canada Checkpoint Inhibitors Market Analysis
14.13.1 Patients Response to Checkpoint Inhibitor Therapies is Low in the Country
14.13.2 Canada Market Is Expected to Grow at a Steady Pase
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Mexico Checkpoint Inhibitors Market Analysis
14.14.1 Mexico Is One of the Research Centres for Checkpoint Inhibitors.
14.14.2 PD-1/PD-L1 Inhibitors Continue to Change the Cancer Treatment Landscape in the Country
14.14.3 Pre-COVID-19 Market Scenario
14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

15 Europe Checkpoint Inhibitors Market Analysis
15.1 Europe Market Outlook
15.2 Europe Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Europe Market Size Estimation and Forecast by Region
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Europe Market Size Estimation and Forecast by Category
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 Europe Market Size Estimation and Forecast by PD1 Inhibitors
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 Europe Market Size Estimation and Forecast by PD-L1 Inhibitors
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 Europe Market Size Estimation and Forecast by CTLA-4 Inhibitors:
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 Europe Market Size Estimation and Forecast by Cytokines Targets:
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 Europe Market Size Estimation and Forecast by Application
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Europe Market Size Estimation and Forecast by Immuno Adjuvants:
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Europe Market Size Estimation and Forecast by Immonumodulators
15.11.1 Pre-COVID-19 Market Scenario
15.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 Germany Checkpoint Inhibitors Market Analysis
15.12.1 German Companies Pursuing Bispecific for The Next Generation of Checkpoint Inhibitors
15.12.2 Companies Are Trying All Kinds of Combinations to Make Checkpoint Inhibitors Work for More People
15.12.3 Pre-COVID-19 Market Scenario
15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 UK Checkpoint Inhibitors Market Analysis
15.13.1 High Tumour Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
15.13.2 UK Checkpoint Inhibitors Market to Grow at a Decent Rate
15.13.3 Pre-COVID-19 Market Scenario
15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 France Checkpoint Inhibitors Market Analysis
15.14.1 Checkpoint Inhibitors Have Proven to Be Powerful Anti-Tumour Drugs
15.14.2 French Companies Facing Failures in Checkpoint Inhibitors Research
15.14.3 Pre-COVID-19 Market Scenario
15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Italy Checkpoint Inhibitors Market Analysis
15.15.1 Immunotherapy, And More Recently as Immuno-Oncology Therapies Are in Demand in The Country
15.15.2 Strong Pharmacovigilance Infrastructure in The Country.
15.15.3 Pre-COVID-19 Market Scenario
15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Spain Checkpoint Inhibitors Market Analysis
15.16.1 Prostate Cancer Is the Third Most Frequent Neoplasms in Spain
15.16.2 Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
15.16.3 Pre-COVID-19 Market Scenario
15.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.17 Rest of Europe Checkpoint Inhibitors Market Analysis
15.17.1 Pre-COVID-19 Market Scenario
15.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

16 Asia-Pacific Checkpoint Inhibitors Market Analysis
16.1 Asia-Pacific Market Outlook
16.1.1 Chinese Checkpoint Inhibitors Are Poised to Change Global Market Dynamics
16.2 Asia-Pacific Market Size Estimation and Forecast
16.2.1 Pre-COVID-19 Market Scenario
16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.3 Country Market Size Estimation and Forecast
16.3.1 Pre-COVID-19 Market Scenario
16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.4 Asia-Pacific Market Breakdown by Category
16.4.1 Pre-COVID-19 Market Scenario
16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.5 Asia-Pacific Market Breakdown by PD-1 Inhibitors
16.5.1 Pre-COVID-19 Market Scenario
16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.6 Asia-Pacific Market Breakdown by PD-L1 Inhibitors
16.6.1 Pre-COVID-19 Market Scenario
16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.7 Asia-Pacific Market Breakdown by CTLA-4 Inhibitors
16.7.1 Pre-COVID-19 Market Scenario
16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.8 Asia-Pacific Market Breakdown by Cytokines Targets
16.8.1 Pre-COVID-19 Market Scenario
16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.9 Asia-Pacific Market Breakdown by Application
16.9.1 Pre-COVID-19 Market Scenario
16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.10 Asia-Pacific Market Breakdown by Immuno Adjuvants
16.10.1 Pre-COVID-19 Market Scenario
16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.11 Asia-Pacific Market Breakdown by Immonumodulators
16.11.1 Pre-COVID-19 Market Scenario
16.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.12 China Checkpoint Inhibitors Market Analysis
16.12.1 China Supporting Local ICI Companies
16.12.2 International ICI Brands Seeking Market Access in China
16.12.3 Pre-COVID-19 Market Scenario
16.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.13 India Checkpoint Inhibitors Market Analysis
16.13.1 Increasing Breast Cancer Patients in India
16.13.2 Surgery Is the Mainstay of Treatment of the Early Stages of Breast Cancer in The Country
16.13.3 Upcoming Other Efficient Treatments such as Checkpoint Inhibitors in the Country
16.13.4 Pre-COVID-19 Market Scenario
16.13.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.14 Japan Checkpoint Inhibitors Market Analysis
16.14.1 Use of Neoadjuvant Trials to Drive Progress in Head and Neck Cancer Immunotherapy
16.14.2 Country is Focusing on Various Application Areas of Checkpoint Inhibitors
16.14.3 Pre-COVID-19 Market Scenario
16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.15 South Korea Checkpoint Inhibitors Market Analysis
16.15.1 More Emphasis Given On Radiation & Immunotherapy as Compared to CHI
16.15.2 The Role of ICIs in Earlier Stages of Disease Is Unclear
16.15.3 Pre-COVID-19 Market Scenario
16.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.16 Australia Checkpoint Inhibitors Market Analysis
16.16.1 Australia Heading the Research on Checkpoint Inhibitors
16.16.2 Triebel spun out the Australian-European immunotherapy company
16.16.3 Pre-COVID-19 Market Scenario
16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.17 Rest of Asia-Pacific Checkpoint Inhibitors Market Analysis
16.17.1 Pre-COVID-19 Market Scenario
16.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

17 LAMEA Checkpoint Inhibitors Market Analysis
17.1 LAMEA Market Outlook
17.2 LAMEA Market Size Estimation and Forecast
17.2.1 Pre-COVID-19 Market Scenario
17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.3 Country Market Size Estimation and Forecast
17.3.1 Pre-COVID-19 Market Scenario
17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.4 LAMEA Market Breakdown by Category
17.4.1 Pre-COVID-19 Market Scenario
17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.5 LAMEA Market Breakdown by PD-1 Inhibitors:
17.5.1 Pre-COVID-19 Market Scenario
17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.6 LAMEA Market Breakdown by PD-L1 Inhibitors:
17.6.1 Pre-COVID-19 Market Scenario
17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.7 LAMEA Market Breakdown by CTLA-4 Inhibitors:
17.7.1 Pre-COVID-19 Market Scenario
17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.8 LAMEA Market Breakdown by Cytokines Targets:
17.8.1 Pre-COVID-19 Market Scenario
17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.9 LAMEA Market Breakdown by Application:
17.9.1 Pre-COVID-19 Market Scenario
17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.10 LAMEA Market Breakdown by Immuno Adjuvants:
17.10.1 Pre-COVID-19 Market Scenario
17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.11 LAMEA Market Breakdown by Immunomodulators:
17.11.1 Pre-COVID-19 Market Scenario
17.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.12 Brazil Checkpoint Inhibitors Market Analysis
17.12.1 Country Adopting Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
17.12.2 Pre-COVID-19 Market Scenario
17.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.13 South Africa Checkpoint Inhibitors Market Analysis
17.13.1 Checkpoint Inhibitors Are Also Being Investigated in Combination with Chemotherapy
17.13.2 Pre-COVID-19 Market Scenario
17.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.14 Saudi Arabia Checkpoint Inhibitors Market Analysis
17.14.1 Increasing Importance of Immune Checkpoint Inhibitor Therapy
17.14.2 Pre-COVID-19 Market Scenario
17.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.15 Turkey Checkpoint Inhibitors Market Analysis
17.15.1 Immune Checkpoint Inhibitor Research Under Trials
17.15.2 Pre-COVID-19 Market Scenario
17.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.16 UAE Checkpoint Inhibitors Market Analysis
17.16.1 Negative Side of ICI Reported in UAE
17.16.2 Pre-COVID-19 Market Scenario
17.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.17 Rest of LAMEA Checkpoint Inhibitors Market Analysis
17.17.1 Pre-COVID-19 Market Scenario
17.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

18 Leading Company Profiles
18.1 Competitive Landscape
18.1.1 Collaborations and Partnerships in the Global Market
18.2 Seagen Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Company Financial Profile
18.2.4 Company Product Benchmarking
18.2.5 Company Recent Developments
18.3 AGENUS INC.
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Company Financial Profile
18.3.4 Company Product Benchmarking
18.3.5 Company Recent Developments
18.4 Agilent Technologies
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Company Financial Profile
18.4.4 Company Product Benchmarking
18.4.5 Company Recent Developments
18.5 AbbVie Inc.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Company Financial Profile
18.5.4 Company Product Benchmarking
18.5.5 Company Recent Developments
18.6 xencor
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Company Financial Profile
18.6.4 Company Product Benchmarking
18.6.5 Company Recent Developments
18.7 Ono pharmaceutical
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Company Financial Profile
18.7.4 Company Product Benchmarking
18.7.5 Company Recent Developments
18.8 Sanofi SA
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Company Financial Profile
18.8.4 Company Product Benchmarking
18.8.5 Company Recent Developments
18.9 Eli Lilly and Co
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Company Financial Profile
18.9.4 Company Product Benchmarking
18.9.5 Company Recent Developments
18.10 Kyowa Hakko Kirin
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Company Financial Profile
18.10.4 Company Product Benchmarking
18.10.5 Company Recent Developments
18.11 Novartis
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Company Financial Profile
18.11.4 Company Product Benchmarking
18.11.5 Company Recent Developments
18.12 Pfizer Inc.
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Company Financial Profile
18.12.4 Company Product Benchmarking
18.12.5 Company Recent Developments
18.13 Roche
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Company Financial Profile
18.13.4 Company Product Benchmarking
18.13.5 Company Recent Developments
18.14 Merck & Co.
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Company Financial Profile
18.14.4 Company Product Benchmarking
18.14.5 Company Recent Developments
18.15 Incyte
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Company Financial Profile
18.15.4 Company Product Benchmarking
18.15.5 Company Recent Developments
18.16 Regeneron pharmaceuticals Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Company Financial Profile
18.16.4 Company Product Benchmarking
18.16.5 Company Recent Developments
18.17 Amgen Inc
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Company Financial Profile
18.17.4 Company Product Benchmarking
18.17.5 Company Recent Developments
18.18 Bristol Myers Squibb
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Company Financial Profile
18.18.4 Company Product Benchmarking
18.18.5 Company Recent Developments
18.19 Clovis Oncology
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Company Financial Profile
18.19.4 Company Product Benchmarking
18.19.5 Company Recent Developments
18.20 Heptares Therapeutics Ltd.
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Company Financial Profile
18.20.4 Company Product Benchmarking
18.20.5 Company Recent Developments

19 Conclusions & Recommendations Visiongain
19.1 Concluding Remarks from Visiongain
19.2 Recommendations for Market Players
19.3 North America to Dominate the Global Checkpoint Inhibitors Market
19.3.1 North America to Hold the Largest Share During Forecast Period
19.3.2 Asia-Pacific Region to Emerge as the Fastest Growing Market

20 Glossary Terms

List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Checkpoint Inhibitors Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 3. Adverse Events Associated with Immune-Checkpoint Blockade
Table 4. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 10. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 14. Comparison of PD-L1-PD-L2 ligands
Table 15. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
Table 16. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications (continued)
Table 17. PD-1/PD-L1 Agents Pipeline Drugs
Table 18. Pembrolizumab Approved Indications
Table 19. Nivolumab Approved Indications
Table 20. Atezolizumab Approved Indications
Table 21. Regeneron’s NSCLC Development Program
Table 22. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 27. Avelumab Approved Indications
Table 28. Durvalumab Approved Indication
Table 29. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 34. CTLA-4 Agents in Pipeline
Table 35. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 36. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 41. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 51. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 56. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 62. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 63. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 64. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 67. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 68. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 69. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 73. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 74. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 78. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 79. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 88. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 89. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 93. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 94. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 98. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 99. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 103. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 104. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 113. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 114. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 118. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 119. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 123. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 124. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 128. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 129. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 134. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 144. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 154. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 159. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 179. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 184. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 189. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 194. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 199. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 204. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 209. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 202